Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Newron Pharmaceuticals
Biotech
FDA hits Newron schizophrenia ph. 3 trial with hold after death
The patient's death was deemed unrelated to treatment, Newron said, and sudden death is more common in people with schizophrenia.
Darren Incorvaia
Apr 29, 2026 2:50pm
Eisai pays $46M for Japan rights to Newron's schizophrenia med
Dec 13, 2024 8:37am
Newron schizophrenia add-on improves positive, negative symptoms
Apr 30, 2024 9:13am
Cerevel swaps CEO—Chutes & Ladders
May 5, 2023 9:30am
Newron's schizophrenia data boost chances of historic approval
Feb 16, 2023 8:30am
Newron ditches sarizotan program after pivotal trial flop
May 4, 2020 7:50am
